Table 1 Characteristics of patients in this study
From: Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
| Â | CD | UC | HS | Indeterminate |
|---|---|---|---|---|
n | 121 | 75 | 27 | 8 |
Female gender (n) | 59.5% (72) | 49.3% (37) | 55.6% (15) | 62.5% (5) |
Age (lower 95%-upper 95%) | 37.3 (34.3-40.3) | 41.1 (37.4-44.9) | 35.1 (29.1-41.2) | 26.9 (13.4-40.3) |
Smoker (n) | Â | Â | Â | Â |
   Never | 63.6% (77) | 57.3% (43) | 85.2% (23) | 75.0% (6) |
   Previously | 24.8% (30) | 40% (30) | 11.1% (3) | 12.5% (1) |
   Current | 10.7% (13) | 2.7% (2) | 0% (0) | 12.5% (1) |
   Unknown | 0.8% (1) | 0% (0) | 3.7% (1) | 0% (0) |
Sample | Â | Â | Â | Â |
   Stool (n) | 51.2% (62) | 64% (48) | 66.7% (18) | 100% (8) |
   Biopsy (n) | 48.8% (59) | 36% (27) | 33.3% (9) | 0% (0) |
Disease | Â | Â | Â | Â |
   Active disease (n)a | 26.4% (32) | 29.3% (22) | 0% (0) | 0% (0) |
   Ileal (n) | 35.5% (43) | NA | NA | NA |
Treatment | Â | Â | Â | Â |
   Mesalamine (n) | 55.4% (67) | 77.3% (58) | 0% (0) | 75.0% (6) |
   Steroids (n) | 31.4% (38) | 37.3% (28) | 0% (0) | 50% (4) |
   Immunosuppressant (n)b | 38.8% (47) | 16% (12) | 0% (0) | 0% (0) |
   Antibiotics (n) | 12.4% (15) | 13.3% (10) | 0% (0) | 12.5% (1) |